Brought to you by 
Fate, Stemgent platform reprograms mature cells as stem cells
28 Aug 2013
Executive Summary
Fate Therapeutics (stem cell biology aimed at modulating cell fate; has a late-preclinical candidate in hematopoietic reconstitution) and Stemgent (reagents for stem cell generation) are creating a program called Catalyst that will offer pharma and biotech clients a platform for drug discovery and development. The technique creates iPS cells--induced pluripotent stem cells--and then re-differentiates them into distinct cell types.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
- Services
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Fate, Stemgent platform reprograms mature cells as stem cells
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice